Intradigm Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$24M
Intradigm General Information
Description
Developer of systematic ribonucleic acid interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's RNAi therapeutics platform includes RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics, and siRNA sequence applications. It develops a portfolio of siRNA sequences against various oncology and other disease targets.
Contact Information
Website
www.intradigm.comCorporate Office
- 3350 West Bayshore Road
- Suite 100
- Palo Alto, CA 94303
- United States
Corporate Office
- 3350 West Bayshore Road
- Suite 100
- Palo Alto, CA 94303
- United States
Intradigm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 05-Jan-2010 | $24M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series B) | 07-Feb-2009 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 21-Nov-2006 | $15.5M | $16.5M | Completed | Product Development | |
| 1. Early Stage VC (Series B1) | 17-Dec-2003 | $1M | $1M | Completed | Generating Revenue |
Intradigm Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | 13,160,000 | $0.010000 | 8% | $1.17 | $1.17 | 1x | $1.17 | 7.01% |
| Series A1 | 6,700,000 | $0.010000 | 8% | $1.17 | $1.17 | 1x | $1.17 | 3.57% |
Intradigm Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Intradigm Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Intradigm Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Daiichi Sankyo | Corporation | Minority | ||
| Emerging Technology Partners (Venture Capital) | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority |
Intradigm FAQs
-
When was Intradigm founded?
Intradigm was founded in 2000.
-
Where is Intradigm headquartered?
Intradigm is headquartered in Palo Alto, CA.
-
What is the size of Intradigm?
Intradigm has 17 total employees.
-
What industry is Intradigm in?
Intradigm’s primary industry is Biotechnology.
-
Is Intradigm a private or public company?
Intradigm is a Private company.
-
What is the current valuation of Intradigm?
The current valuation of Intradigm is .
-
What is Intradigm’s current revenue?
The current revenue for Intradigm is .
-
How much funding has Intradigm raised over time?
Intradigm has raised $37.9M.
-
Who are Intradigm’s investors?
Alta Partners, Astellas Venture Management, Daiichi Sankyo, Emerging Technology Partners (Venture Capital), and Frazier Healthcare Partners are 5 of 10 investors who have invested in Intradigm.
-
When was Intradigm acquired?
Intradigm was acquired on 05-Jan-2010.
-
Who acquired Intradigm?
Intradigm was acquired by Silence Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
